Expertise in
41
conditions

Dr. Andrew T. Kuykendall

Hematology Oncology | Internal Medicine
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
41
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Andrew Kuykendall is an Internal Medicine provider practicing medicine in Tampa, Florida.

Dr. Kuykendall is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 122 peer reviewed articles and participating in 9 clinical trials. Dr. Kuykendall is currently accepting new patients.

Graduate Institution

University Of Florida College Of Medicine

Specialties

Hematology Oncology
Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Enrollment Status: Completed
Publish Date: June 09, 2026
Intervention Type: Drug
Study Phase: Phase 2
Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2026
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug, Biological
Study Drug: CD8-Depleted Donor Lymphocyte Infusion
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Enrollment Status: Terminated
Publish Date: December 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Drug
Study Drugs: Canakinumab, Darbepoetin Alfa
Study Phase: Phase 1/Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Enasidenib
Study Phase: Phase 2
View 8 Less Clinical Trials

122 Total Publications

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.
Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.
Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Hassan M. Ebrahim
Hematology Oncology | Hematology | Oncology
Expertise in
28
conditions
Dr. Hassan M. Ebrahim
Hematology Oncology | Hematology | Oncology
Referral may be required

MidFlorida Oncology

635 1st St N, 
Winter Haven, FL 
 (42.3 miles away)
863-292-4670
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Hassan Ebrahim is board certified in medical oncology, hematology and internal medicine. He earned his Doctor of Medicine and Surgery from the University of Alexandria Medical School in Alexandria, Egypt. He then completed an internal medicine residency at Howard University in Washington, DC, followed by a fellowship in hematology and oncology. Dr. Ebrahim has an extensive background in hematology and oncology, having contributed his expertise to a number of institutions throughout the southeastern United States. In addition, Dr. Ebrahim was a medical oncologist consultant to the King Fahad Specialist Hospital in Dammam, Saudi Arabia. He is a member of the American Society of Clinical Oncology, the American Society of Hematology and the American College of Physicians. Dr. Ebrahim treats all blood disorders and cancers. He has contributed articles to numerous publications on breast cancer. Additionally, his clinical interests include, gastrointestinal cancers, lung cancer, prostate cancer, lymphomas and blood disorders. Dr. Ebrahim is fluent in Arabic. Dr. Ebrahim is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Pleuropulmonary Blastoma, Angiosarcoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Ebrahim is board certified in AB Internal Medicine - Internal Medicine, AB Internal Medicine (Medical Oncology), and AB Internal Medicine (Hematology). Dr. Ebrahim is currently accepting new patients.

Expertise in
4
conditions
Dr. Jaekyung Cheon
Hematology Oncology | Oncology | Hematology
Expertise in
4
conditions
Dr. Jaekyung Cheon
Hematology Oncology | Oncology | Hematology
Referral may be required
12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-745-4673
Languages Spoken:
English

Jaekyung Cheon is a Hematologist Oncology specialist and an Oncologist practicing medicine in Tampa, Florida. Dr. Cheon is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Agranulocytosis, Febrile Neutropenia, and Bone Marrow Transplant.

Expertise in
7
conditions
Dr. Muaz A. Alrazzak
Hematology Oncology
Expertise in
7
conditions
Dr. Muaz A. Alrazzak
Hematology Oncology
Referral may be required
Before you request

Johns Hopkins All Children's Outpatient Care, Tampa

12220 Bruce B Downs Boulevard, 
Tampa, FL 
 (2.0 miles away)
727-767-4176
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Alrazzak specializes in pediatric hematology and oncology in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute in St. Petersburg, Florida. He joined the hospital staff in 2024. He was previously an attending physician in pediatric hematology and oncology and chair of the Department of Pediatrics at Palm Beach Children’s Hospital in West Palm Beach, Florida. He earned his medical degree from University of Aleppo in Syria. He completed a pediatric residency at Miami Children’s Hospital, followed by a fellowship in pediatric hematology and oncology at State University of New York at Buffalo. He speaks English and Arabic. Dr. Alrazzak is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), and Hemoglobin SC Disease. Dr. Alrazzak is board certified in American Board Of Pediatrics. Dr. Alrazzak is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew T. Kuykendall

How do I make an appointment with Dr. Andrew T. Kuykendall?

You can book an appointment with Dr. Andrew T. Kuykendall by calling their office at 813-701-3769. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew T. Kuykendall a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew T. Kuykendall is classified as an Elite expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew T. Kuykendall specialize in?

While Dr. Andrew T. Kuykendall is a Hematology Oncology, they have specific expertise in Myelofibrosis, Polycythemia Vera, and Myeloproliferative Neoplasms (MPN). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Andrew T. Kuykendall participate in research or clinical trials?

Yes. Dr. Andrew T. Kuykendall has published 122 articles and abstracts on conditions like Myelofibrosis. You can view a list of Dr. Andrew T. Kuykendall's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew T. Kuykendall accept my insurance?

Dr. Andrew T. Kuykendall accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-701-3769 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kuykendall's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 9 Distinguished Conditions
View All 24 Advanced Conditions
View All 91 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile